Literature DB >> 8151742

Measurement of platelet-activating factor in human blood by high performance thin layer chromatography and its clinical application.

H P Li1, R X Zhang.   

Abstract

Platelet-activating factor (PAF) present in the blood of the patients with chronic pulmonary heart disease and asthma has been detected by high performance thin layer chromatography (HPTLC). The patients with chronic pulmonary heart disease accompanied by carbon dioxide retention (PaCO2 > 6.67 kPa) have a higher level of PAF in blood (0.75 +/- 0.27 microgram/ml) than those who have no carbon dioxide retention (PaCO2 < 6.67 kPa, PAF 0.41 +/- 0.25 microgram/ml) and those in the normal control group (0.45 +/- 0.20 microgram/ml), with P < 0.05 in all. The patients with asthma have a higher PAF in blood (0.83 +/- 0.05 microgram/ml) than those in the control group (P < 0.005). These findings suggest that PAF plays an important role in episodes of chronic pulmonary heart disease and asthma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8151742     DOI: 10.1007/bf02888015

Source DB:  PubMed          Journal:  J Tongji Med Univ        ISSN: 0257-716X


  5 in total

1.  A rapid method of total lipid extraction and purification.

Authors:  E G BLIGH; W J DYER
Journal:  Can J Biochem Physiol       Date:  1959-08

2.  Aggregation of blood platelets by adenosine diphosphate and its reversal.

Authors:  G V BORN
Journal:  Nature       Date:  1962-06-09       Impact factor: 49.962

3.  Physicochemical and functional identity of rabbit platelet-activating factor (PAF) released in vivo during IgE anaphylaxis with PAF released in vitro from IgE sensitized basophils.

Authors:  R N Pinckard; R S Farr; D J Hanahan
Journal:  J Immunol       Date:  1979-10       Impact factor: 5.422

4.  Presence in normal human urine of a hypotensive and platelet-activating phospholipid.

Authors:  M Sánchez-Crespo; P Iñarrea; V Alvarez; F Alonso; J Egido; L Hernando
Journal:  Am J Physiol       Date:  1983-06

5.  Effects of the platelet-activating factor antagonist BN 52021 on the hemodynamics of rats with experimental cirrhosis of the liver.

Authors:  L M Villamediana; E Sanz; S Fernandez-Gallardo; C Caramelo; M Sanchez Crespo; P Braquet; J M Lopez-Novoa
Journal:  Life Sci       Date:  1986-07-21       Impact factor: 5.037

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.